Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C.

Hepatology (Baltimore, Md.) - 1 Apr 2015

Cunningham Morven E, Javaid Alia, Waters Jenny, Davidson-Wright Joseph, Wong Joshua L C, Jones Meleri, Foster Graham R

Abstract excerpt

UNLABELLED: Emerging therapies for chronic hepatitis C viral (HCV) infection involve inhibition of viral enzymes with drug combinations. Natural, or treatment-induced, enzyme polymorphisms reduce efficacy. We developed a phenotyping assay to aid drug selection based on viral transfer from monocytes to hepatocytes. We studied HCV in monocytes from infected patients and developed a model in which patient-derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Fusion
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepacivirus

Share to Hepatocytes

Share to Inhibitory Concentration 50

Share to Monocytes

Share to Oligopeptides

Source

Identifiers

PMID: 25330450
DOI: 10.1002/hep.27570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C.PMID 25330450Read ↗

Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.Semantic proximity Read ↗

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Semantic proximity Read ↗

Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.Semantic proximity Read ↗

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.Semantic proximity Read ↗

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral AgentsSemantic proximity Read ↗

A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV.Semantic proximity Read ↗

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.Semantic proximity Read ↗

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.Semantic proximity Read ↗

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.Semantic proximity Read ↗

Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesSemantic proximity Read ↗

Evolution of cell culture systems for HCV.Semantic proximity Read ↗

SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.